r
c
l
e
n
f
merscov
rna
viru
one
inhibitor
sar
optim
b
r
c
one
deriv
synthes
evalu
show
high
antimerscov
inhibitori
activ
among
amino
one
exhibit
high
inhibitori
effect
ic
nm
low
toxic
cc
moreov
show
good
metabol
stabil
low
herg
bind
affin
cytotox
good
vivo
pk
properti
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
fatal
viru
caus
sever
respiratori
symptom
human
high
mortal
high
fever
cough
short
breath
acut
pneumonia
merscov
zoonot
coronaviru
spread
nonsustain
persontoperson
transmiss
travelrel
merscov
infect
continu
spread
arabian
peninsula
sever
countri
caus
epidem
high
fatal
rate
merscov
singlestrand
positivesens
rna
viru
use
host
cellular
compon
accomplish
variou
physiolog
process
includ
intern
virion
genom
replic
packag
bud
virion
therefor
stage
step
viru
life
cycl
target
therapeut
inhibit
screen
fdaapprov
drug
merscov
identifi
mani
drug
antivir
effect
drug
categor
inhibitor
disrupt
endocytosi
interrupt
merscov
rna
replic
translat
inhibitor
undefin
mechan
date
still
approv
antivir
drug
therefor
develop
therapeut
mer
receiv
attent
began
investig
screen
compound
korean
chemic
bank
kcb
merscov
use
high
content
screen
hc
platform
institut
pasteur
korea
ipk
effort
isopropylamino
trifluoromethyl
one
identifi
primari
hit
fig
deriv
show
broad
rang
pharmacolog
activ
antibacteri
antineurodegen
antiinfammatori
report
synthesi
biolog
effect
one
deriv
seri
analogu
synthes
use
scheme
amid
prepar
either
reaction
diketen
anilin
presenc
basic
catalyst
condens
reaction
substitutedacetyl
acet
anilin
bi
methylthio
compound
synthes
react
amid
carbon
disulfid
dimethylsulf
presenc
potassium
carbon
reflux
bi
methylthio
compound
inert
solvent
like
transform
one
treatment
one
hydrogen
peroxid
acet
acid
lead
correspond
sulfoxid
reactiv
substitut
reaction
nucleophil
substitut
reaction
variou
amin
sulfoxid
afford
one
antimerscov
activ
synthes
compound
vero
cell
infect
korean
clinic
merscov
isol
http
doit
determin
monitor
cell
express
viral
spike
protein
use
immunofluoresc
assay
ifa
extens
sar
investig
assess
effect
moieti
substitu
aryl
variou
amin
shown
tabl
start
sar
studi
vari
substitu
posit
quinolon
ring
compound
fix
acetyl
group
posit
isopropyl
amin
posit
compound
electron
donat
group
show
inhibitori
effect
applic
phenyl
substitu
posit
detriment
inhibitori
effect
substitu
posit
result
signific
higher
activ
ic
given
benefici
effect
posit
explor
effect
electronwithdraw
group
lefthand
ring
quinolon
part
prepar
analogu
replac
c
trifluoromethyl
fluorin
nitro
function
posit
moder
toler
ic
respect
deriv
also
retain
inhibitori
effect
ic
respect
observ
show
electronwithdraw
substitu
leftr
quinolon
scaffold
fruit
inhibitori
activ
electrondon
substitu
detriment
next
substitu
effect
posit
one
scaffold
evalu
although
less
activ
quinolon
deriv
ic
group
substitu
analogu
open
possibl
extens
explor
sar
studi
via
modif
posit
therefor
focus
optim
one
piperidin
morpholin
nbutyl
amin
posit
show
inhibitori
effect
alcohol
amin
moder
toler
ic
respect
wherea
amin
amin
function
detriment
bind
affin
compound
show
inhibitori
effect
indic
anilin
substitu
electrondon
group
detriment
group
show
similar
inhibitori
effect
ic
respect
analogu
display
increas
inhibitori
effect
ic
investig
wide
rang
substitu
effect
posit
anilin
group
electronwithdraw
substitu
show
high
bind
affin
next
phase
optim
substitu
effect
posit
investig
benzoyl
substitu
posit
complet
abolish
activ
pivaloyl
group
posit
block
nucleophil
substitut
anilin
posit
compound
isobutyryl
substitu
posit
deepli
examin
compound
includ
anilin
group
posit
show
higher
inhibitori
effect
correspond
compound
acetyl
group
posit
ic
respect
compound
substitu
posit
also
display
higher
inhibitori
effect
ic
respect
correspond
one
compound
substitu
posit
also
show
potent
biolog
activ
ic
respect
note
compound
except
display
obviou
cytotox
cc
compound
found
potent
merscov
inhibitor
evalu
metabol
stabil
herg
cytotox
vivo
pharmacokinet
profil
tabl
display
good
metabol
stabil
human
rat
mous
liver
microsom
show
low
herg
bind
affin
cytotox
toward
vero
nih
cell
line
exhibit
good
oral
bioavail
promis
c
max
auc
valu
clearanc
summari
develop
novel
class
one
base
merscov
inhibitor
system
sar
optim
lead
compound
compound
includ
isobutyryl
substitu
posit
group
good
merscov
inhibitor
ic
nm
addit
substanc
show
good
metabol
stabil
low
herg
bind
affin
cytotox
good
vivo
pk
properti
oral
bioavail
rat
futur
optim
one
base
merscov
inhibitor
fig
hit
compound
obtain
ht
one
deriv
synthes
evalu
show
high
antimerscov
inhibitori
activ
among
amino
one
exhibit
high
inhibitori
effect
ic
nm
low
toxic
cc
moreov
show
good
metabol
stabil
low
herg
bind
affin
cytotox
good
vivo
pk
properti
middl
east
respiratori
syndrom
coronaviru
merscov
emerg
fatal
viru
caus
sever
respiratori
symptom
human
high
mortal
high
fever
cough
short
breath
acut
pneumonia
merscov
zoonot
coronaviru
spread
nonsustain
persontoperson
transmiss
travelrel
merscov
infect
continu
spread
arabian
peninsula
sever
countri
caus
epidem
high
fatal
rate
merscov
singlestrand
positivesens
rna
viru
use
host
cellular
compon
accomplish
variou
physiolog
process
includ
intern
virion
genom
replic
packag
bud
virion
therefor
stage
step
viru
life
cycl
target
therapeut
inhibit
screen
fdaapprov
drug
merscov
identifi
mani
drug
antivir
effect
drug
categor
inhibitor
disrupt
endocytosi
interrupt
merscov
rna
replic
translat
inhibitor
undefin
mechan
date
still
approv
antivir
drug
therefor
develop
therapeut
mer
receiv
attent
began
investig
screen
compound
korean
chemic
bank
kcb
merscov
use
high
content
screen
hc
platform
institut
pasteur
korea
ipk
effort
isopropylamino
trifluoromethyl
one
identifi
primari
hit
fig
deriv
show
broad
rang
pharmacolog
activ
antibacteri
antineurodegen
antiinfammatori
report
synthesi
biolog
effect
one
deriv
seri
analogu
synthes
use
scheme
amid
prepar
either
reaction
diketen
anilin
presenc
basic
catalyst
condens
reaction
substitutedacetyl
acet
anilin
bi
methylthio
compound
synthes
react
amid
carbon
disulfid
dimethylsulf
presenc
potassium
carbon
reflux
bi
methylthio
compound
inert
solvent
like
transform
one
treatment
one
hydrogen
peroxid
acet
acid
lead
correspond
sulfoxid
reactiv
substitut
reaction
nucleophil
substitut
reaction
variou
amin
sulfoxid
afford
one
antimerscov
activ
synthes
compound
vero
cell
infect
korean
clinic
merscov
isol
determin
monitor
cell
express
viral
spike
protein
use
immunofluoresc
assay
ifa
extens
sar
investig
assess
effect
moieti
substitu
aryl
variou
amin
shown
tabl
start
sar
studi
vari
substitu
posit
quinolon
ring
compound
fix
acetyl
group
posit
isopropyl
amin
posit
compound
electron
donat
group
show
inhibitori
effect
applic
phenyl
substitu
posit
detriment
inhibitori
effect
substitu
posit
result
signific
higher
activ
ic
given
benefici
effect
posit
explor
effect
electronwithdraw
group
lefthand
ring
quinolon
part
prepar
analogu
replac
c
trifluoromethyl
fluorin
nitro
function
posit
moder
toler
ic
respect
deriv
also
retain
inhibitori
effect
ic
respect
observ
show
electronwithdraw
substitu
leftr
quinolon
scaffold
fruit
inhibitori
activ
electrondon
substitu
detriment
next
substitu
effect
posit
one
scaffold
evalu
although
less
activ
quinolon
deriv
ic
group
substitu
analogu
open
possibl
extens
explor
sar
studi
via
modif
posit
therefor
focus
optim
one
piperidin
morpholin
nbutyl
amin
posit
show
inhibitori
effect
alcohol
amin
moder
toler
ic
respect
wherea
amin
amin
function
detriment
bind
affin
compound
show
inhibitori
effect
indic
anilin
substitu
electrondon
group
detriment
group
show
similar
inhibitori
effect
ic
respect
analogu
display
increas
inhibitori
effect
ic
investig
wide
rang
substitu
effect
posit
anilin
group
electronwithdraw
substitu
show
high
bind
affin
next
phase
optim
substitu
effect
posit
investig
benzoyl
substitu
posit
complet
abolish
activ
pivaloyl
group
posit
block
nucleophil
substitut
anilin
posit
compound
isobutyryl
substitu
posit
deepli
examin
compound
includ
anilin
group
posit
show
higher
inhibitori
effect
correspond
compound
acetyl
group
posit
ic
respect
compound
substitu
posit
also
display
higher
inhibitori
effect
ic
respect
correspond
one
compound
substitu
posit
also
show
potent
biolog
activ
ic
respect
note
compound
except
display
obviou
cytotox
cc
compound
found
potent
merscov
inhibitor
evalu
metabol
stabil
herg
cytotox
vivo
pharmacokinet
profil
tabl
display
good
metabol
stabil
human
rat
mous
liver
microsom
show
low
herg
bind
affin
cytotox
toward
vero
nih
cell
line
exhibit
good
oral
bioavail
promis
c
max
auc
valu
clearanc
summari
develop
novel
class
one
base
merscov
inhibitor
system
sar
optim
lead
compound
compound
includ
isobutyryl
substitu
posit
group
good
merscov
inhibitor
ic
nm
addit
substanc
show
good
metabol
stabil
low
herg
bind
affin
cytotox
good
vivo
pk
properti
oral
bioavail
rat
futur
optim
one
base
merscov
inhibitor
vivo
efficaci
anim
model
mainli
perform
due
cours
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
data
microsom
stabil
herg
cytotox
vivo
pharmacokinet
profil
